Dear Colleagues,

We are pleased to invite you to the 6th International Sublobar Resections and Evolving Techniques for Lung Cancer Conference which will take place on May 13–14, 2027, in Seoul, South Korea, in conjunction with the 41st Spring Meeting of the Korean Society for Thoracic and Cardiovascular Surgery.

Since its inception, the International Sublobar Conference has become a leading forum for specialists dedicated to advancing the management of early-stage lung cancer. Building on the success of previous editions, ISC 2027 will once again bring together the international surgical and interventional community to discuss the evolving role of sublobar treatment. In particular, this edition will also consider how segmentectomy may find its place in the de-escalation of treatment after neoadjuvant immuno-chemotherapy.

As evidence continues to reshape clinical practice, important questions remain regarding patient selection, oncologic quality, long-term outcomes, and the optimal treatment strategy for each patient. This new edition will explore how advances in surgery, technology, and precision medicine are transforming the management of early-stage lung cancer.

The conference will highlight the latest developments in segmentectomy, robotic and minimally invasive surgery, and the management of elderly and high-risk patients. While segmentectomy remains at its heart, ISC 2027 will also explore emerging lung-preserving approaches, including bronchoscopic ablation, image-guided interventions, and biology-driven strategies, highlighting how these innovations are shaping more personalized treatment in early-stage lung cancer.

Looking ahead, discussions will explore how biomarkers, artificial intelligence, and other innovations may help guide treatment decisions and shape the future of personalized lung cancer care.

By bringing together leading experts from around the world, the conference will provide a unique opportunity to share experience, discuss recent advances, and explore the future of our field.

We look forward to welcoming you to Seoul for two days of scientific exchange, collaboration and innovation.

Best regards,